Axsome Therapeutics (AXSM Quick QuoteAXSM - Free Report) reported $150.04 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 72.1%. EPS of -$0.92 for the same period compares to -$1.24 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $139.61 million, representing a surprise of +7.47%. The company delivered an EPS surprise of +8%, with the consensus EPS estimate being -$1.00.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Axsome performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Royalty: $1.08 million versus the nine-analyst average estimate of $1.74 million. The reported number represents a year-over-year change of +67.7%.
• Revenues- Product sales, net: $148.96 million versus the nine-analyst average estimate of $135.37 million. The reported number represents a year-over-year change of +72.2%.
• Product Sales, net- Sunosi: $30 million versus the six-analyst average estimate of $25.75 million.
• Product Sales, net- Auvelity: $119.6 million compared to the $110.79 million average estimate based on six analysts.

View all Key Company Metrics for Axsome here>>>

Shares of Axsome have returned -2.3% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.